OVIDNasdaqPharmaceutical PreparationsFiscal year ends December 31

Ovid Therapeutics Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026

$2.17+0.02 (+0.93%)

Close on Oct 19, 2026

Market cap: –
P/E (TTM): –
Dividend yield: –

Ovid Therapeutics Inc. income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31
Revenue	7.25	0.57	0.39	1.50	208	13	–	–	–	–	–
Research & Development	26	37	29	25	47	63	42	34	50	9.59	6.61
General & Administrative	24	26	31	32	37	31	19	19	15	13	6.58
Operating Expenses	50	62	60	57	84	94	61	53	65	23	13
Operating Income	-42	-62	-59	-56	124	-81	-61	-53	-65	-23	-13
Interest & Investment Income	2.03	3.92	4.94	–	–	–	–	–	–	–	–
Other Non-Operating Income	25	35	6.94	1.38	-0.05	–	0.95	0.95	0.20	0.12	0.03
Pretax Income	-17	-26	-52	-54	124	-81	–	–	–	–	–
Income Tax Expense	0	0	0	0	1.33	0	0	0	0	–	–
Net Income	-17	-26	-52	-54	123	-81	-60	-52	-65	-22	-13
Net Income to Common	-17	-26	-51	-54	120	-81	-60	-52	-65	-22	-13
EPS (Basic)(per share)	–	–	-0.74	-0.77	1.78	-1.39	–	-2.11	-3.35	-2.28	-1.36
EPS (Diluted)(per share)	–	–	-0.74	-0.77	1.76	-1.39	–	-2.11	-3.35	-2.28	-1.36
Shares Outstanding (Basic, Weighted)(shares)	–	–	71	70	67	58	–	25	19	9.84	9.70
Shares Outstanding (Diluted, Weighted)(shares)	–	–	71	70	68	58	–	25	19	9.84	9.70
EBITDA	-42	-61	-59	-55	124	-81	-61	-53	-65	-22	-13

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: –
Operating margin: -3686.7%
Net margin: -2178.9%
Return on equity, FY2025: -17.5%

Financial strength

Current ratio: 12.39
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 113.5%

Valuation

P/E ratio: –
Price to sales: –
Price to book: –
Dividend yield: –